Communiqués Captor Therapeutics Spolka Akcyjna

Actions

Temps Différé Warsaw S.E. 15:21:44 17/08/2026			Varia. 5j.	Varia. 1 janv.
70,00 ^PLN	-2,78%		+0,14%	-2,78%

27/05	Captor Therapeutics : perte nette de 11.4 millions de zlotys au premier trimestre	RE
27/05	Captor Therapeutics Spolka Akcyjna publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

30/05/23	Captor Therapeutics Publishes Q1 2023 Financial Results	AQ
28/03/23	Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast	AQ
07/03/23	Captor Therapeutics Announces Three-Year Strategic Objectives	AQ
28/11/22	Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical	AQ
25/11/22	Captor Therapeutics Reports Q3 2022 Results and Provides Business Update	AQ
14/11/22	Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases	AQ
10/08/22	Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma	AQ
05/05/22	Captor Therapeutics to Host R&D Day on May 18, 2022	GL
05/05/22	Captor Therapeutics to Host R&D Day on May 18, 2022	AQ
12/04/22	Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma	AQ
11/04/22	Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022	GL
13/01/22	Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	GL
13/01/22	Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	GL